Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Vertex Pharmaceuticals Incorporated Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 86.23||$ 143.45|
|Low||$ 83.40||$ 75.90|
The current last sale of $84.39 is 11.19% Higher thanthe 52 week low.
ETFs with VRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.56%||PowerShares Dynamic Biotech &Genome (PBE)||-8.63 (-17.62%)|
|4.03%||Market Vectors Biotech ETF (BBH)||-10.90 (-9.08%)|
|3.61%||iShares Nasdaq Biotechnology Index Fund (IBB)||-46.70 (-14.50%)|
|1.51%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||-13.75 (-19.95%)|
|0.13%||PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (PRFZ)||+0.88 (0.90%)|
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative drugs for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Cystic Fibrosis Our goal is twofold: to develop treatment regimens that will provide benefits to as many patients with CF as possible and to enhance those benefits. Our two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ... More ...
Where does VRTX fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$-2.07|
|Quarterly EPS Est:||0.24|